[1]
|
Wang, W., Jiang, B., Sun, H., et al. (2017) Prevalence, Incidence, and Mortality of Stroke in China: Results from a Na-tionwide Population-Based Survey of 480 687 Adults. Circulation, 135, 759-771.
https://doi.org/10.1161/CIRCULATIONAHA.116.025250
|
[2]
|
Borén, J. and Williams, K.J. (2016) The Central Role of Arterial Retention of Cholesterol-Rich Apolipoprotein-B-Containing Lipoproteins in the Pathogenesis of Athero-sclerosis: A Triumph of Simplicity. Current Opinion in Lipidology, 27, 473-483. https://doi.org/10.1097/MOL.0000000000000330
|
[3]
|
Libby, P., Buring, J.E., Badimon, L., et al. (2019) Athero-sclerosis. Nature Reviews Disease Primers, 5, Article No. 56.
https://doi.org/10.1038/s41572-019-0106-z
|
[4]
|
Ference, B.A., Ginsberg, H.N., Graham, I., et al. (2017) Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38, 2459-2472.
https://doi.org/10.1093/eurheartj/ehx144
|
[5]
|
Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., et al. (2013) Familial Hypercholesterolaemia Is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 34, 3478-3490.
https://doi.org/10.1093/eurheartj/eht273
|
[6]
|
Amarenco, P. and Labreuche, J. (2009) Lipid Management in the Pre-vention of Stroke: Review and Updated Meta-Analysis of Statins for Stroke Prevention. The Lancet Neurology, 8, 453-463.
https://doi.org/10.1016/S1474-4422(09)70058-4
|
[7]
|
Baigent, C., Keech, A., Kearney, P.M., et al. (2005) Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Ran-domised Trials of Statins. Lancet, 366, 1267-1278.
https://doi.org/10.1016/S0140-6736(05)67394-1
|
[8]
|
Guan, Z.-W., Wu, K.-R., Li, R., et al. (2019) Pharmaco-genetics of Statins Treatment: Efficacy and Safety. Journal of Clinical Pharmacy and Therapeutics, 44, 858-867. https://doi.org/10.1111/jcpt.13025
|
[9]
|
Istvan, E.S. and Deisenhofer, J. (2001) Structural Mechanism for Statin In-hibition of HMG-CoA Reductase. Science, 292, 1160-1164. https://doi.org/10.1126/science.1059344
|
[10]
|
Sirtori, C.R. (2014) The Pharmacology of Statins. Pharmacological Research, 88, 3-11.
https://doi.org/10.1016/j.phrs.2014.03.002
|
[11]
|
Brown, M.S. and Goldstein, J.L. (1997) The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor. Cell, 89, 331-340. https://doi.org/10.1016/S0092-8674(00)80213-5
|
[12]
|
任新宇, 周玉杰, 马茜. 他汀类药物作用机制的研究进展[J]. 中国医药, 2016, 11(3): 442-447.
|
[13]
|
Ridker, P.M., Danielson, E., Fonseca, F.A., et al. (2008) Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 359, 2195-2207.
https://doi.org/10.1056/NEJMoa0807646
|
[14]
|
Downs, J.R., Clearfield, M., Weis, S., et al. (1998) Primary Preven-tion of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels: Results of AFCAPS/TexCAPS. JAMA, 279, 1615-1622.
https://doi.org/10.1001/jama.279.20.1615
|
[15]
|
Mangravite, L.M., Thorn, C.F. and Krauss, R.M. (2006) Clinical Implications of Pharmacogenomics of Statin Treatment. The Pharmacogenomics Journal, 6, 360-374. https://doi.org/10.1038/sj.tpj.6500384
|
[16]
|
Krauss, R.M., Mangravite, L.M., Smith, J.D., et al. (2008) Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated with Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment. Circulation, 117, 1537-1544. https://doi.org/10.1161/CIRCULATIONAHA.107.708388
|
[17]
|
Donnelly, L.A., Doney, A.S., Dannfald, J., et al. (2008) A Paucimorphic Variant in the HMG-CoA Reductase Gene Is Associated with Lipid-Lowering Response to Statin Treatment in Diabetes: A GoDARTS Study. Pharmacogenetics and Genomics, 18, 1021-1026. https://doi.org/10.1097/FPC.0b013e3283106071
|
[18]
|
Cuevas, A., Fernández, C., Ferrada, L., et al. (2016) HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals. Basic & Clinical Pharmacology & Toxicology, 118, 292-297.
https://doi.org/10.1111/bcpt.12493
|
[19]
|
Cano-Corres, R., Candás-Estébanez, B., Padró-Miquel, A., et al. (2018) Influence of 6 Genetic Variants on the Efficacy of Statins in Patients with Dyslipidemia. Journal of Clinical Laboratory Analysis, 32, e22566.
https://doi.org/10.1002/jcla.22566
|
[20]
|
Medina, M.W., Gao, F., Ruan, W., Rotter, J.I. and Krauss, R.M. (2008) Alternative Splicing of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Is Associated with Plasma Low-Density Lipoprotein Cholesterol Response to Simvastatin. Circulation, 118, 355-362. https://doi.org/10.1161/CIRCULATIONAHA.108.773267
|
[21]
|
Bays, H., Cohen, D.E., Chalasani, N. and Harri-son, S.A. (2014) An Assessment by the Statin Liver Safety Task Force: 2014 Update. Journal of Clinical Lipidology, 8, S47-S57. https://doi.org/10.1016/j.jacl.2014.02.011
|
[22]
|
Talameh, J.A. and Kitzmiller, J.P. (2014) Pharmacogenet-ics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants. Journal of Pharmacogenomics & Pharmacoproteomics, 5, Article ID: 100012. https://doi.org/10.4172/2153-0645.1000128
|
[23]
|
Sivkov, A., Chernus, N., Gorenkov, R., et al. (2021) Relationship between Genetic Polymorphism of Drug Transporters and the Efficacy of Rosuvastatin, atorvastatin and simvastatin in Patients with Hyperlipidemia. Lipids in Health and Disease, 20, Article No. 157. https://doi.org/10.1186/s12944-021-01586-7
|
[24]
|
Tudorache, I.F., Trusca, V.G., and Gafencu, A.V. (2017) Apolipoprotein E—A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Fea-tures. Computational and Structural Biotechnology Journal, 15, 359-365. https://doi.org/10.1016/j.csbj.2017.05.003
|
[25]
|
刘艳辉, 董婧, 陆燕, 等. SLCO1B1521 T>C和APOE基因多态性对阿托伐他汀调脂疗效及安全性的影响[J]. 药学实践杂志, 2021, 39(3): 245-248.
|
[26]
|
高辉, 王杨, 陈婉婷, 卫波. SLCO1B1和APOE基因多态性与他汀类药物疗效的相关性[J]. 实用医学杂志, 2019, 35(14): 2300-2303.
|
[27]
|
Mahley, R.W. (2016) Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Me-tabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 36, 1305-1315. https://doi.org/10.1161/ATVBAHA.116.307023
|
[28]
|
Neumann, J., Rose-Sperling, D and Hellmich, U.A. (2017) Diverse Relations between ABC Transporters and Lipids: An Overview. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1859, 605-618.
https://doi.org/10.1016/j.bbamem.2016.09.023
|
[29]
|
Fukunaga, K., Nakagawa, H., Ishikawa, T., Kubo, M. and Mushiroda, T. (2016) ABCB1 Polymorphism Is Associated with Atorvastatin-Induced Liver Injury in Japanese Popula-tion. BMC Genomic Data, 17, Article No. 79.
https://doi.org/10.1186/s12863-016-0390-5
|
[30]
|
Hoenig, M.R., Walker, P.J., Gurnsey, C., Beadle, K. and Johnson, L. (2011) The C3435T Polymorphism in ABCB1 Influences Atorvastatin Efficacy and Muscle Symptoms in a High-Risk Vascular Cohort. Journal of Clinical Lipidology, 5, 91-96. https://doi.org/10.1016/j.jacl.2011.01.001
|
[31]
|
Gu, G.-L., Xu, X.-L., Yang, Q.-Y. and Zeng, R.-L. (2014) Effect of CETP Polymorphism on Atorvastatin Lipid-Regulating Effect and Clinical Prognosis of Patients with Coronary Heart Disease. Medical Science Monitor, 20, 2824-2829. https://doi.org/10.12659/MSM.892711
|
[32]
|
Gao, J., Cong, H.L., Mao, Y.M., et al. (2013) Influence of CETP Gene-629C/A Polymorphism on the Efficacy of Atorvastatin Treatment and Clinical Outcome. Chinese Journal of Medi-cal Genetics, 30, 553-558. (In Chinese)
|
[33]
|
Rader, D.J. and Degoma, E.M. (2014) Future of Cholesteryl Ester Trans-fer Protein Inhibitors. Annual Review of Medicine, 65, 385-403. https://doi.org/10.1146/annurev-med-050311-163305
|
[34]
|
Kitzmiller, J.P., Binkley, P.F., Pandey, S.R., et al. (2013) Statin Pharmacogenomics: Pursuing Biomarkers for Predicting Clinical Outcomes. Discovery Medicine, 16, 45-51.
|